Core Viewpoint - The article emphasizes the importance of the "2026 Global Health Industry Innovation Conference" to promote high-quality development in the health sector, driven by innovative technologies like AI and big data, aligning with national strategies for health and innovation [1][3]. Group 1: Conference Overview - The conference titled "汇智·无界" will take place on January 18, 2026, at the Zhongguancun International Innovation Center in Beijing [1][13]. - It aims to gather experts from various fields, including government officials, academicians, and industry representatives, to discuss the future of the health industry and explore innovative solutions [3][13]. Group 2: Key Themes and Topics - The conference will focus on the transformative impact of digital technologies on healthcare, including precision diagnostics, intelligent treatment, and comprehensive health management [3]. - Various parallel forums will address topics such as AI-driven medical services, innovations in urology, and the integration of traditional Chinese medicine with modern technology [15][17]. Group 3: Notable Speakers - Distinguished speakers include academicians from the Chinese Academy of Engineering and the Chinese Academy of Sciences, as well as leaders from major healthcare institutions and pharmaceutical companies [6][19]. - Keynote presentations will cover topics like AI in clinical research, intelligent medical imaging, and the development of new healthcare ecosystems [17][19]. Group 4: Supporting Organizations - The conference is supported by various institutions, including the Beijing Health Commission and several prominent hospitals and universities, highlighting a collaborative approach to healthcare innovation [13][21]. - Strategic partners include major pharmaceutical companies and technology firms, indicating a strong industry backing for the event [13][21].

微创脑科学（02172）盘中涨超5%，截至发稿，股价上涨3.77%，报11.29港元，成交额637.89万港元。 微创医疗公布，终止合并微创脑科学，原因是微创脑科学在委任一名独立非执行董事后，公司根据会计 政策认为无法控制微创脑科学但仍保持重大影响力。终止合并预期将确认视同处置附属公司收益。 责任编辑：卢昱君 微创脑科学（02172）盘中涨超5%，截至发稿，股价上涨3.77%，报11.29港元，成交额637.89万港元。 微创医疗公布，终止合并微创脑科学，原因是微创脑科学在委任一名独立非执行董事后，公司根据会计 政策认为无法控制微创脑科学但仍保持重大影响力。终止合并预期将确认视同处置附属公司收益。 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 责任编辑：卢昱君 ...

公司通过聚焦核心业务、优化资源配置等措施，盈利能力显著改善。在国内外复杂环境下，公司25H1 实现收入5.48亿美元，同比下降2.0%；净亏损由上年同期的1.07亿美元大幅收窄至3636万美元，经营拐 点显现。盈利改善主要得益于费用管控成效显著：公司运营费率同比优化8.1个百分点，研发费率从 20.6%降至13.2%；此前公司公告将完成相关业绩目标：2025年上半年净亏损不超过1.1亿美元、2025年 全年净亏损不超过5500万美元、2026年上半年净利润不少于4500万美元、2026年全年净利润不少于9000 万美元。整体来看，公司正在通过聚焦业务、提高收入、降低费用等各项举措实现大幅减亏。 风险提示：高值耗材降价超预期、骨科减亏低于预期、收购整合风险等。 治理结构改善注入新动能，出海业务成为核心增长引擎 公司治理层面，上实资本旗下基金成为公司重要战略股东，有望在治理和业务发展方面注入新动能。公 司近期完成心律管理与结构性心脏病业务的重组，旨在打造综合心脏病平台，新公司将融合微创心律管 理的AI诊断及算法技术，与微创心通在结构性心脏病介入治疗、输送系统及生物材料方面的技术积 累，打造"结构性心脏病+心律管理 ...

Summary of Key Points Core Viewpoint - Vili Medical (603309) has experienced a slight decline in stock price, with a current market capitalization of 3.967 billion yuan, ranking 87th in the medical device sector and 3948th in the A-share market [1]. Company Announcements - Vili Medical announced a cash dividend of 0.2 yuan per share (before tax) for Q3 2025, with the record date set for January 7, 2026, and the payment date on January 8, 2026. The total cash dividend distribution amounts to approximately 58.37 million yuan based on a total share count of 291,871,418 shares [1][3]. - The wholly-owned subsidiary, Jiangxi Langhe Medical Device Co., Ltd., has received re-certification as a high-tech enterprise, valid for three years from October 29, 2025. This allows the subsidiary to continue benefiting from a 15% corporate income tax rate from 2025 to 2027 [2][3]. - The controlling shareholder, Gaobo Investment (Hong Kong) Co., Ltd., has released a pledge on 20 million shares, which represents 6.85% of the total share capital. As of December 31, 2025, Gaobo Investment holds 31.53% of the company's shares, with a total of 26 million shares pledged [2][3].

祥生医疗2025年第三次临时股东会于2025年12月30日召开，审议通过《关于2025年前三季度利润分配方 案的议案》。会议由董事会召集，董事长莫若理主持，采取现场与网络投票结合方式，出席股东25名， 代表表决权80,361,392股，占公司总表决权的71.6708%。议案获普通股股东99.9987%同意，中小投资者 同意比例为99.9903%，反对股占比0.0013%，无弃权。上海市通力律师事务所见证会议全过程，并出具 法律意见书，认为会议召集、召开程序、表决结果等均符合法律法规及公司章程规定，决议合法有效。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总：祥生医疗2025年第三次临时股东会审议通过前三季度利润分配方案，获99.9987% 股东同意。 公司公告汇总：中小投资者对利润分配方案的支持率达99.9903%，显示高度认可。 公司公告汇总：股东会表决结果合法有效，上海市通力律师事务所出具法律意见书确认合规性。 截至2025年12月26日收盘，祥生医疗（688358）报收于30.1元，较上周的30.55元下跌1. ...

天臣医疗关于选举第三届董事会职工代表董事的公告 天臣国际医疗科技股份有限公司于2025年12月29日召开职工代表大会，选举周云女士为公司第三届董事 会职工代表董事，任期至第三届董事会任期届满。周云女士现任公司总裁办主任，持有公司0.03%股 份，与控股股东、实际控制人及其他董事无关联关系，具备董事任职资格。本次选举产生的职工代表董 事将与公司2026年第一次临时股东会选举产生的董事共同组成第三届董事会。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年12月26日收盘，天臣医疗（688013）报收于54.6元，较上周的48.2元上涨13.28%。本周，天 臣医疗12月26日盘中最高价报56.99元。12月24日盘中最低价报46.58元。天臣医疗当前最新总市值39.02 亿元，在医疗器械板块市值排名88/127，在两市A股市值排名3990/5181。 本周关注点 公司公告汇总：选举周云女士为第三届董事会职工代表董事。 公司公告汇总 ...

Core Viewpoint - As of December 26, 2025, Xinmai Medical (688016) closed at 93.43 yuan, reflecting a 0.68% increase from the previous week, with a total market capitalization of 11.298 billion yuan [1] Company Announcements - Xinmai Medical elected Sun Hongbin, Liang Min, and Liu Xudong as non-independent directors of the third board, with each receiving over 99% of the votes [1] - Beijing Jiayuan Law Firm provided a legal opinion confirming that the procedures for the second extraordinary general meeting of shareholders held on December 31, 2025, complied with the Company Law and the company's articles of association, deeming the meeting valid [1] - The second extraordinary general meeting of shareholders approved the election of Sun Hongbin, Liang Min, and Liu Xudong as non-independent directors, with a voting power representation of 42.6305% from attending shareholders [1]

公司公告汇总 截至2025年12月26日收盘，春立医疗（688236）报收于23.71元，较上周的24.84元下跌4.55%。本周， 春立医疗12月22日盘中最高价报24.99元。12月24日盘中最低价报23.53元。春立医疗当前最新总市值 87.76亿元，在医疗器械板块市值排名40/127，在两市A股市值排名2144/5181。 本周关注点 公司公告汇总：春立医疗2025年第二次临时股东大会审议通过取消监事会及修订多项治理制度的 议案。 北京市万商天勤律师事务所出具法律意见书，确认本次股东大会的召集、召开程序、出席会议人员资 格、召集人资格、表决程序及表决结果均符合相关法律法规及公司章程规定，会议决议合法有效。本次 股东大会审议通过了关于取消监事会并修订《公司章程》、修订《股东会议事规则》和《董事会议事规 则》的议案，各项议案均已获得出席股东所持表决权的三分之二以上通过。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 北京市春立正达医疗器械股份有限公司于2025年12月29日召开2025年第二次临时股东大会，会议由董事 会召集， ...

Core Viewpoint - Anbiping (688393) has experienced a decline in stock price and market capitalization, with significant shareholder reductions and developments in its business related to digital pathology and AI-assisted diagnostics [1][2][3]. Group 1: Stock Performance and Shareholder Changes - As of December 26, 2025, Anbiping's stock closed at 23.99 yuan, down 3.85% from the previous week [1]. - The total market capitalization of Anbiping is 2.217 billion yuan, ranking 121 out of 127 in the medical device sector and 5001 out of 5181 in the A-share market [1]. - From December 1 to December 30, 2025, major shareholders reduced their holdings by a total of 685,800 shares, representing 0.7329% of the company's total equity [2]. Group 2: Institutional Research Insights - The National Healthcare Security Administration's new guidelines on pathology services are relevant to Anbiping, particularly regarding digital slide scanning and case report uploads, which could incur penalties if not provided [3]. - Anbiping's cervical cytology product is currently in the registration process, with the potential for new revenue streams from auxiliary diagnostic services [3]. - The company has over 300 medical institutions collaborating on its scanning equipment as of the first half of 2025 [4]. Group 3: AI and Digital Tools in Diagnostics - The integration of AI in pathology diagnostics is expected to enhance efficiency, with previous tests showing a reduction in diagnosis time from 218 seconds per slide to 30 seconds [6][7]. - Anbiping plans to negotiate with local healthcare and pricing departments to implement new pricing structures for AI-assisted diagnostics [5][6]. - The company is also expanding its AI capabilities beyond cervical cytology, with ongoing projects in immunohistochemistry and fluorescence scanning [7]. Group 4: Company Announcements - Anbiping will hold its first extraordinary general meeting of 2026 on January 14, 2026, to discuss the election of a non-independent director [8]. - The company announced the resignation of two senior executives and the nomination of a new non-independent director candidate, pending shareholder approval [8].

雾化器参数看不懂？德国PARI教你认清这两个标准，闭眼选不踩坑！ 买雾化器时，面对MMD、TOR、可吸入比例、RDDR 一堆专业参数，是不是瞬间犯晕？选便宜的怕效果差，选贵的又担心被 "虚标参数" 坑？其实不用纠 结，跟着德国PARI分清两个关键标准，就能轻松选出靠谱设备，让每一分钱都花在刀刃上！ 首先要明确：雾化器的核心是 "让药物精准抵达肺部"，参数靠不靠谱，先看测试标准是否贴合真实治疗场景；参数好不好用，再看新标准下的具体数值。 目前行业有两个核心测试标准，差别直接影响治疗效果，看懂就能避开大半坑！ 旧标准（激光衍射法）：理想状态的 "纸面数据" 很多老款雾化器还在用旧标准测试的参数，旧标准核心是激光衍射法 + 持续固定气流测量。这种方式下测出来的参数往往特别 "好看"—— 比如可吸入比例 能标到65%以上，TOR（总输出率）数值也格外亮眼，但这些数据都是 "实验室理想状态" 的结果，和实际使用场景有比较大的差距。 举个直观例子：旧标准测可吸入比例时，用的是固定不变的气流（比如成人 20l/min）和0.9% 生理盐水，完全不考虑人呼吸时"吸气-呼气"的节律变化，也忽 略了环境湿度、温度对雾化效果的影响 ...